Iambic Therapeutics: CFO Michael Secora received 61,342 shares

What happened

• Michael Secora, chief financial officer and chief corporate development officer, converted a derivative security into 61,342 shares of common stock on Oct 16, 2026. The filing shows an acquisition of 61,342 shares at N/A and a related disposition of 61,342 shares at $0.00 (derivative).

Key details

• Transaction date: Oct 16, 2026; filing date: Oct 19, 2026.
• Price/amounts reported: acquired 61,342 shares at N/A; disposed 61,342 shares at $0.00.
• Shares owned after the transaction: not reported in this filing.
• Footnote F1: each share of Series B-3 convertible preferred stock automatically converted into common stock on a one-to-one basis immediately prior to the completion of the issuer's initial public offering of common stock and had no expiration date.
• The filing does not indicate whether it was late.

Why it may matter

• This was a conversion of a derivative security into common stock (not a market purchase or sale).
• The filing does not show why the insider traded or why the company acted.